Microsoft word - guidelines for poster.doc

National Symposium on
Innovation in TB Diagnostics, Drug Targets and Biomarkers
C.M.E. On Innovation in Molecular and Immunodiagnostics for PTB & EPTB in
India
(*Supported by KHS, AstraZeneca, ICMR, DBT, CSIR, DST & MCI) January 27 –28, 2014
JB Tropical Disease Research Centre, Mahatma Gandhi Institute of Medical Sciences, Sevagram - Poster Session:
There will be a poster session on 27th January, 2014 during 1.00 – 2.30 PM. Posters may be on the theme of ‘TB Diagnostics, Drug Targets and Biomarkers’ and related topics
covering Research findings.
POSTER PRESENTATION FORM
Title*: …………………………………………………………………………………………………………………………………….
…………………………………………………….………………………………………………………………………………………… 1. Name of the Candidate: ………………………………………………………………………………………………….
2. Designation ……………………………………………………………………………………….
3. Name of the Guide: ……………………………………………………………………………………………………….
4. Name of the Institute & Address: ….………………………………………………………………………………
…………………………………………………………………………………………………………………………………………… 5. Specialization ………………………………………………………………………………………………………………….

* see guidelines for poster presentation.
Signature of Candidate
Guidelines for Poster
1. Original research papers are invited for presentation 2. Abstract not exceeding 250 words. Sample abstract enclosed:
Wankhade G, Hutke V, Waghmare PJ, Misra AK, Varma SK, Harinath BC. Inhibitory effect of isoniazid and orlistat combination on mycobacterial ES-31 serine protease in vitro and on the growth of M.tb bacilli in axenic culture. Indian J Tuberc. 2012 Jul;59(3):156-61. JB Tropical Disease Research Centre, Mahatma Gandhi Institute of Medical Sciences, Sevagram - 442 102, District - Wardha, Maharashtra. info@jbtdrc.org BACKGROUND: Isoniazid and orlistat were reported to have inhibitory effect on mycobacterial ES-31 serine protease in vitro and bacterial cell growth in axenic culture. AIM: To study the cumulative effect and understand drug - drug interaction, if any, when isoniazid and orlistat used in combination. MATERIAL AND METHODS: Inhibition of mycobacterial ES-31 serine protease by different combinations of orlistat and isoniazid together and individually were studied using azocasein assay. Inhibition of secretion of excretory secretory ES-31 antigen in Sautan culture medium was studied under axenic condition and growth of M. tuberculosis H37Ra bacilli by CFU count on LJ-medium. RESULTS: Orlistat and isoniazid both showed inhibitory activity of ES-31 serine protease in in vitro as well as in vivo. Individually, isoniazid showed 90% inhibition at 200 ng/ml while orlistat at 250 ng/ml showed 65% inhibition of mycobacterial ES-31 serine protease in vitro. A combination of orlistat (250 ng/ml) and isoniazid (200 ng/ml) showed 86% inhibition in vitro while 73% inhibition was observed by orlistat (25 ng/ml) and isoniazid (200 ng/ml) on bacterial CONCLUSION: Significant inhibition by orlistat suggests that it could be tried in patients with intolerance to isoniazid or in those already developed isoniazid resistance. It may also be explored in the suspected TB patients as initial medication in place of antibiotics for clinical 3. A space of 3’X 4’ (36” X 48”) will be allotted for the poster. Title, Introduction / Background, Objectives, Materials and Methods / Experimental 5. Poster should have heading and includes the title, the name(s) of the author(s) and 6. Presenting author should be underlined. 7. Presenting author should get registered for the Symposium. 8. The participants are required to fix their posters before 12.30 PM. Your poster is to remain on view for 1 ½ hour. (YOU ARE EXPECTED TO BE AT YOUR POSTER TO DISCUSS YOUR
RESULTS WITH ATTENDEES AND JUDGES).
If extenuating circumstances prevent you from being present during your scheduled time, you are expected to make arrangements to have a co-author take your place. 9. Filled Application Form along with Abstract should be sent to the Organising Secretary before 30th November, 2013.

Source: http://www.jbtdrc.org/Guidelines_for_Poster.pdf